Getting Started

Welcome to the CIBMTR Forms Instruction Manual. The Table of Contents on the left side of the screen is for navigational purposes; if you are on a mobile device you may find the Table on Contents on the top of the page.

General Instructions provides useful general background information for successfully completing forms.

2804/2814: CRID Assignment and Indication provides explanatory text used to generate a CIBMTR Research ID (CRID) and report the indication.

Transplant Essential Data (TED) Manuals provides explanatory text for each question found on the TED forms.

Comprehensive Baseline & Follow-up Forms Manuals provides explanatory text for each question on the Baseline, Follow-up, IDMs, HLA, and Infusion forms.

Comprehensive Disease Specific Manuals provides explanatory text and additional information for disease indications requiring CIBMTR reporting.

Cellular Therapy Manuals provides explanatory text for completing pre-infusion, infusion, and post-infusion forms

Infection & Miscellaneous Manuals provides explanatory text for manuals such as the Hepatitis Serology, VOD / SOS, and Myelofibrosis CMS Study forms.

Appendices provide additional information beyond the scope of the other manuals.

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. In addition to documenting the changes within each manual section, the most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

Date	Manual Section	Add/Remove/Modify	Description
4/24/26	4100: Cellular Therapy Essential Data Follow-Up	Modify	Added examples of other neurotoxicities that should be reported in question 157: Other: Examples of other neurotoxicities to report include, but are not limited to, hallucinations, speech impairment (dysphasia or aphasia), dysgraphia, personality change.
4/24/26	4100: Cellular Therapy Essential Data Follow-Up	Modify	Added clarification to COVID-19 reporting scenarios for question 194: only COVID infections that were treated should be reported. Possible COVID-19 Reporting Scenarios: Do NOT report an infection in the following scenarios: A recipient has a positive antibody result. The recipient was symptomatic and treated but COVID-19 testing was not performed and / or COVID-19 diagnostic testing was performed and negative * The recipient was diagnosed with COVID-19 but no treatment was given DO report an infection in the follow scenarios: A recipient has a positive COVID-19 diagnostic result (PCR or antigen) and was treated A recipient has a positive antibody result and a positive COVID-19 diagnostic test (PCR or antigen) and was treated
4/24/26	4100: Cellular Therapy Essential Data Follow-Up	Add	Added an example for colitis for question 23: Colitis: inflammation of the colon (e.g. immune effector cell-associated enterocolitis (IEC-EC))
4/24/2026	4100: Cellular Therapy Essential Data Follow-Up	Modify	Clarified the intent of question 161: Replacement therapy is given to prevent infections. If the recipient received immunoglobulin replacement therapy (includes, but not limited to, IVIG or SCIG) for any reason (regardless of hypogammaglobulinemia that developed post-infusion), select Yes. Specify the initial intent of the reason the recipient received immunoglobulin therapy:
4/24/2026	4100: Cellular Therapy Essential Data Follow-Up	Modify	Updated the examples for prophylaxis vs replacement immunoglobulin replacement therapy in question 161: Select Prophylaxis if: • The recipient receives immunoglobulin replacement therapy for any reason (e.g. infection, treatment for cranial nerve palsy) and did not fulfill the hypogammaglobulinemia criteria the recipient did not fulfill the hypogammaglobulinemia criteria but still received immunoglobulin therapy. • If the recipient was initially given IVIG as prophylaxis but it becomes replacement therapy for hypogammaglobulinemia still report as Prophylaxis since that was the original intent. % Select Replacement if: the recipient did fulfill the hypogammaglobulinemia criteria (as noted below). %(color-red)• The recipient did fulfill the hypogammaglobulinemia criteria (as noted below) • Documentation says immunoglobulin replacement therapy due to hypogammaglobulinemia / B-cell aplasia • Recipient was initially given IVIG as replacement, but it becomes prophylaxis for hypogammaglobulinemia
4/24/2026	4100: Cellular Therapy Essential Data Follow-Up	Modify	Question 164, clarified the intent of question with a better description: The intent of this question is to capture if immunoglobulin therapy, given either for prophylaxis and / or replacement, was stopped in the current reporting period. For the reason reported above (e.g. prophylaxis vs replacement), specify if immunoglobulin therapy was discontinued in the reporting period. If Yes, report the date of last immunoglobulin therapy infusion given. Do not report Yes if the recipient died in the reporting period.
4/24/26	2058/2158: Thalassemia / 2058: Thalassemia Pre-Infusion	Add	Blue note box added to question 2: *Beta-globin genotype*- The option values provided on the form are the standard representations. A result of “B0/BE” is the same as “BE/B0”. This applies to all the option values.
4/24/26	2058/2158: Thalassemia / 2058: Thalassemia Pre-Infusion	Add	Blue note box added to question 5: Alpha-globin genotype -The option values provided on the form are the standard representations. A result of “aa / —” is the same as “— / aa”. This applies to all the option values.
4/24/2026	2548: Exagamglogene autotemcel (Casgevy®) Pre-Infusion Supplemental Data	Modify	Added clarification that VOC episodes requiring hospitalization or treatment should be reported, to align with the Sickle Cell Disease Pre-Infusion (2030) Form: Indicate the total number of vaso-occlusive pain episodes requiring hospitalization or treatment (i.e., ER admission, day hospital, inpatient admission, etc.) in the 12 months prior to the start of the preparative regimen.
4/24/226	2548: Exagamglogene autotemcel (Casgevy®) Pre-Infusion Supplemental Data	Add	Added sentence in red to clarify if there are multiple collection days: Specify the recipient’s most recent MCV value prior to collection of the infused product. If the recipient has had multiple collections across multiple days, then report values prior to the first collection on the first day.
4/24/2026	2548: Exagamglogene autotemcel (Casgevy®) Pre-Infusion Supplemental Data	Add	Added sentence in red to clarify if there are multiple collection days: If multiple labs are available, use the one closest to the collection start time, even if it is from the same day. If the recipient has had multiple collections across multiple days, then report values prior to the first collection on the first day.
4/24/2026	2548: Exagamglogene autotemcel (Casgevy®) Pre-Infusion Supplemental Data	Add	Added sentence in red to clarify which assessment to use: Report the most recent assessment performed prior to product collection. If no assessment was performed immediately prior to collection, a historical value within 12 months of the infusion date may be used..
4/24/26	2100: Post-Infusion Follow-Up	Modify	Added clarification to COVID-19 reporting scenarios: only COVID infections that were treated should be reported. Possible COVID-19 Reporting Scenarios: Do NOT report an infection in the following scenarios: - A recipient has a positive antibody result. - The recipient was symptomatic and treated but COVID-19 testing was not performed and / or COVID-19 diagnostic testing was performed and negative – The recipient was diagnosed with COVID-19 but no treatment was given DO report an infection in the follow scenarios - A recipient has a positive COVID-19 diagnostic result (PCR or antigen), regardless of if treatment was given or if the recipient was asymptomatic and was treated - A recipient has a positive antibody result and a positive COVID-19 diagnostic test (PCR or antigen) and was treated
4/24/2026	3504: Organ Function / Late Effects	Add	Added red warning box above question 29 to clarify the question apply only to 100d and 6 month timepoints: Thrombotic Microangiopathy (TMA) questions can only be completed on the 100-day and 6-month follow-up forms. These questions will be disabled for all subsequent reporting periods.
4/24/2026	3504: Organ Function / Late Effects	Modify	Clarified intent of reporting seizures in Q115: Seizures are sudden, involuntary muscle contractions due to hyperexcitation of neurons. Indicate if the recipient experienced a seizure(s) in the current reporting period. The intent of this question is to capture each the first instance of a seizure occurring in the reporting period. If the recipient did not have a seizure in the current reporting period or is unknown, select No.
4/24/2026	3504: Organ Function / Late Effects	Modify	Removed the Reporting Multiple Seizures blue note box and updated instructions for reporting the seizure onset date in Q116: Reporting Multiple Seizures: Complete Date of a seizure(s) onset question to report multiple seizures by adding an additional instance in the FormsNet3SM application. Specify the date of the seizure. If multiple seizures occurred in the reporting period, only the first seizure needs to be reported. If multiple seizures occurred in one day, only one instance is required to capture the seizures occurring that day; multiple instances for the same day are not required.
4/24/2026	3504: Organ Function / Late Effects	Add	Clarified intent of the successful extubation question in Q17 – 18: Indicate if the recipient was successfully extubated during the reporting period. The intent of this question is to capture if the outcome of the recipient was successful. If Yes, report the date extubated. If the recipient was extubated multiple times within the reporting period, report the last date extubated. If the recipient was not successfully extubated, passed away while intubated, or was transitioned to comfort care, select No.
4/24/2026	3504: Organ Function / Late Effects	Modify	Replaced Reporting Multiple CAD blue box with Reporting Coronary Artery Disease (CAD) red warning box above Q70: Reporting Multiple Coronary Artery Diseases: Complete Was coronary artery disease present through Date coronary artery disease onset questions to report multiple coronary artery diseases by adding an additional instance in the FormsNet3SM application. Reporting Coronary Artery Disease (CAD): Only the first instance of CAD needs to be reported. Once it has been reported that CAD Developed or Persisted post-infusion, do not continue to report it, regardless if it resolved in a prior reporting period and recurred in the current reporting period and / or was present in a prior reporting period and persisted into the current reporting period (excluding, a pre-infusion diagnosis persisting into the Day 100 (for HCT) or into the one-year reporting period (without resolution since the pre-infusion diagnosis) (for cellular therapy)).
4/24/2026	3504: Organ Function / Late Effects	Modify	Updated instructions for reporting persistent and developed in Q70: Coronary artery disease is the damage or disease in the major blood vessels of the heart. Coronary artery disease is also knowns as CAD and atherosclerotic heart disease. Indicate if coronary artery disease was present in the current reporting period. Report Developed in the following scenarios: – This is the first time the recipient was diagnosed with coronary artery disease in the reporting period. – Coronary artery disease resolved in a prior reporting period and then recurred in the current reporting period. If coronary artery disease Developed, report the onset date. If the diagnosis was determined at an outside center and no documentation of a clinical, pathological, or laboratory assessment is available, the dictated date of diagnosis within a physician note may be reported. For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms Report Persisted in the following scenarios: – Coronary artery disease was diagnosed pre-infusion and persisted into the Day 100 reporting period. – Coronary artery disease was diagnosed (or persisted) in the prior reporting period and persisted into the current reporting period. – For cellular therapy, if coronary artery disease was diagnosed pre-infusion and persisted into the one-year reporting period (without resolution since the pre-infusion diagnosis) as this form will not come due until the one-year reporting period. If coronary artery disease was not present in the current reporting period or unknown if present, select Not present.
4/24/2026	2450: Post-TED	Modify	Updated when to use the persistent disease option in Q78: Persistent disease: The recipient was in primary induction failure or relapse not in a hematologic CR at the time of infusion and has not achieved a hematologic CR post-infusion. This option is used when there is persistent disease or in cases where there is worsening disease but has not met the progression criteria (i.e., a recipient with MDS who is in NR / SD and has worsening cytopenias. PD cannot be reported as HI has not been previously achieved).
4/24/2026	3504: Organ Function / Late Effects	Add	Clarified intent of Q153 – 154 and when to report ‘not present’: Cataracts are the loss of transparency in the lens of the eye. Indicate if cataracts were present in the current reporting period. The intent of this question is only to capture the first occurrence of the impairment / disorder in the recipient’s post-infusion course. The impairment / disorder should be reported once, in the reporting period in which it first meets the criteria for reporting. After the impairment / disorder is reported once post-infusion, it should never be reported again. ; If cataracts were reported as Developed or Persisted in a prior reporting period (regardless of it recurred), not present in the current reporting period, or unknown if present, select Not present.
4/24/2026	3504: Organ Function / Late Effects	Add	Clarified intent of Q163 – 164 and when to report ‘not present’: Mucositis is the inflammation and ulceration of mucous membranes that line the digestive tract, usually due to chemotherapy and radiotherapy. Specify if mucositis was present in the current reporting period. Indicate if mucositis requiring therapy was present in the current reporting period. The intent of this question is only to capture the first occurrence of the impairment / disorder in the recipient’s post-infusion course. The impairment / disorder should be reported once, in the reporting period in which it first meets the criteria for reporting. After the impairment / disorder is reported once post-infusion, it should never be reported again. ; If mucositis was reported as Developed or Persisted in a prior reporting period (regardless of it recurred), not present in the current reporting period, or unknown if present, select Not present.
4/24/2026	3504: Organ Function / Late Effects	Add	Clarified intent of Q146 – 147 and when to report ‘not present’: Osteoporosis is where the bones become weak and brittle due to losing bone mass faster than it is created from aging. Indicate if osteoporosis was present in the current reporting period. The intent of this question is only to capture the first occurrence of the impairment / disorder in the recipient’s post-infusion course. The impairment / disorder should be reported once, in the reporting period in which it first meets the criteria for reporting. After the impairment / disorder is reported once post-infusion, it should never be reported again. ; If osteoporosis was reported as Developed or Persisted in a prior reporting period (regardless of it recurred), not present in the current reporting period or unknown if present select Not present.
4/24/2026	3504: Organ Function / Late Effects	Add	Clarified intent of Q134 – 135 and when to report ‘not present’: Gonadal dysfunction requiring hormone replacement affects both males and females. Males experience decreased spermatogenesis and females may experience early symptoms of menopause, including amenorrhea. Low levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), and / or testosterone may require hormone replacement therapy. Indicate if gonadal dysfunction requiring hormone replacement was present in the current reporting period. The intent of this question is only to capture the first occurrence of the impairment / disorder in the recipient’s post-infusion course. The impairment / disorder should be reported once, in the reporting period in which it first meets the criteria for reporting. After the impairment / disorder is reported once post-infusion, it should never be reported again. ; If gonadal dysfunction requiring hormone replacement was reported as Developed or Persisted in a prior reporting period (regardless of it recurred), not present in the current reporting period, or unknown if present, select Not present.
4/24/2026	3504: Organ Function / Late Effects	Add	Clarified intent of Q125 and when to report ‘not present’: Indicate if growth hormone deficiency / short stature was present in the current reporting period. The intent of this question is only to capture the first occurrence of the impairment / disorder in the recipient’s post-infusion course. The impairment / disorder should be reported once, in the reporting period in which it first meets the criteria for reporting. After the impairment / disorder is reported once post-infusion, it should never be reported again. ; If growth hormone deficiency / short stature was reported as Developed or Persisted in a prior reporting period (regardless of it recurred), not present in the current reporting period or unknown if present, select Not present.
4/24/2026	3504: Organ Function / Late Effects	Add	Clarified intent of Q130 and when to report ‘not present’: Indicate if hypothyroidism requiring replacement therapy was present in the current reporting period. The intent of this question is only to capture the first occurrence of the impairment / disorder in the recipient’s post-infusion course. The impairment / disorder should be reported once, in the reporting period in which it first meets the criteria for reporting. After the impairment / disorder is reported once post-infusion, it should never be reported again. ; If hypothyroidism requiring replacement therapy was reported as Developed or Persisted in a prior reporting period (regardless of it recurred), not present in the current reporting period or unknown if present, select Not present.
4/24/2026	3504: Organ Function / Late Effects	Add	Clarified intent of Q132 – 133 and when to report ‘not present’: Indicate if pancreatitis were present in the current reporting period. The intent of this question is only to capture the first occurrence of the impairment / disorder in the recipient’s post-infusion course. The impairment / disorder should be reported once, in the reporting period in which it first meets the criteria for reporting. After the impairment / disorder is reported once post-infusion, it should never be reported again. ; If pancreatitis was reported as Developed or Persisted in a prior reporting period (regardless of it recurred), not present in the current reporting period or unknown if present, select Not present.
4/24/2026	3504: Organ Function / Late Effects	Add	Clarified intent of Q64 – 65 and when to report ‘not present’: Congestive heart failure (CHF) is the inability of the heart to supply oxygenated blood to meet the body’s needs, with an ejection fraction < 40%. Indicate if congestive heart failure was present in the current reporting period. intent of this question is only to capture the first occurrence of the impairment / disorder in the recipient’s post-infusion course. The impairment / disorder should be reported once, in the reporting period in which it first meets the criteria for reporting. After the impairment / disorder is reported once post-infusion, it should never be reported again. ; If congestive heart failure was reported as Developed or Persisted in a prior reporting period (regardless of it recurred), not present in the current reporting period, or unknown if present, select Not present.
4/24/2026	3504: Organ Function / Late Effects	Add	Clarified intent of Q21 and when to report ‘not present’: Cirrhosis is a degenerative disease in which fibrous tissue forms and the lobes become filled with fat. Cirrhosis may be diagnosed using a liver biopsy, but clinical symptoms (enlarged liver), blood tests, laparoscopy, or radiology imaging are often used to determine the diagnosis of cirrhosis when a liver biopsy is not necessary. Indicate if cirrhosis was present in the current reporting period. The intent of this question is only to capture the first occurrence of the impairment / disorder in the recipient’s post-infusion course. The impairment / disorder should be reported once, in the reporting period in which it first meets the criteria for reporting. After the impairment / disorder is reported once post-infusion, it should never be reported again. ; If cirrhosis was reported as Developed or Persisted in a prior reporting period (regardless of it recurred), not present in the current reporting period, or unknown if present, select Not present.
4/24/2026	2058: Thalassemia Pre-Infusion	Add	CIBMTR Study CS22-24 blue note box added above Q113: CIBMTR Study CS22-24: The Laboratory Studies (3502) and Marrow Surveillance (3506) forms will only come due for Zyntelgo® infusions enrolled in CIBMTR study CS22-24.
4/24/2026	2158: Thalassemia Post-Infusion	Add	CIBMTR Study CS22-24 blue note box added above Q122: CIBMTR Study CS22-24: The Laboratory Studies (3502) and Marrow Surveillance (3506) forms will only come due for Zyntelgo® infusions enrolled in CIBMTR study CS22-24.
4/24/2026	2037: Leukodystrophies Post-Infusion	Add	CIBMTR Study CS20-51 blue note box added above Q72: CIBMTR Study CS20-51: The Laboratory Studies (3502) and Marrow Surveillance (3506) forms will only come due for Skysona® infusions enrolled in CIBMTR study CS20-51.
4/24/2026	2137: Leukodystrophies Post-Infusion	Add	CIBMTR Study CS20-51 blue note box added above Q62: CIBMTR Study CS20-51: The Laboratory Studies (3502) and Marrow Surveillance (3506) forms will only come due for Skysona® infusions enrolled in CIBMTR study CS20-51.
4/24/2026	2130 SCD Post-Infusion	Add	Sickle Cell Gene Therapy Infusions blue note box added above Q161: Sickle Cell Gene Therapy Infusions: The Laboratory Studies (3502) Form and Marrow Surveillance (3506) Form will not come due for sickle cell gene therapy infusions.
4/24/2026	2030 SCD Pre-Infusion	Add	Sickle Cell Gene Therapy Infusions blue note box added above Q138: Sickle Cell Gene Therapy Infusions: The Laboratory Studies (3502) and Marrow Surveillance (3506) forms will not come due for sickle cell gene therapy infusions.
4/24/2026	2116: PCD Post-Infusion	Add	Clarified a 24 hour urine is needed to report the urine immunofixation in Q234: Urine immunofixation is a laboratory technique that detects and types monoclonal antibodies or immunoglobulins in the urine. Indicate if the results of a 24-hour urinary immunofixation at the time of evaluation for this reporting period is Known or Unknown. If Unknown or Not applicable, continue with question 237. Report Not applicable for recipients with non-secretory myeloma.
4/24/2026	2116: PCD Post-Infusion	Add	Clarified a 24 hour urine is needed to report the urine immunofixation in Q25: Urine immunofixation is a laboratory technique that detects and types monoclonal antibodies or immunoglobulins in the urine. Indicate if the results of a 24-hour urinary immunofixation at the time of best response are Known or Unknown. If Unknown or Not applicable, continue with question 28. Report Not applicable for recipients with non-secretory myeloma.
4/24/2026	2016: PCD Pre-Infusion	Add	Clarified a 24 hour urine is needed to report urine immunofixation in Q210: Urine immunofixation is a laboratory technique that detects and types monoclonal antibodies or immunoglobulins in the urine. Indicate if the results of a 24-hour urinary immunofixation at the last evaluation prior to the start of the preparative regimen are Known or Unknown. If Unknown or Not applicable, continue with question 213. Report Not applicable for recipients with non-secretory myeloma.
4/24/2026	2402: Disease Classification	Add	Clarified how to report diagnostic assessments when supportive / palliative therapy is given in the Assessments at Diagnosis of PCD blue note box above Q512: Assessments at Diagnosis of PCD: Report laboratory results closest to the diagnosis date and prior to the start of first treatment of the primary disease for which the infusion is being performed. Supportive care and palliative therapy, such as palliative radiation or Zometa infusions, excluding steroids, should not be considered treatment of disease when determining eligible laboratory values.
4/24/2026	2158: Thalassemia Post-Infusion	Modify	Corrected time point for reporting GFR in Q72 – 73: The glomerular filtration rate (GFR) estimates how much blood passes through the glomeruli each minute and is used to check how well the kidneys are working. Indicate whether the GFR was measured prior to the start of the preparative regimen / infusion in the current reporting period. If measured, select Known and report the laboratory value and unit of measure documented on the laboratory report. If testing was performed multiple times, report the most recent laboratory value obtained. If the GFR was not measured or if no information is available to determine if the GFR was assessed, report Unknown.
4/24/2026	3504: Organ Function / Late Effects	Add	Table 1. When the Organ Function / Late Effects (3504) Comes Due for Stand Alone Infusions and Table 2. When the Organ Function / Late Effects (3504) Comes Due for Combined Follow-Up added to the introduction page. The previous Table 1. Organ Impairments / Disorders Enabled Based on Infusion Type is now Table 3. Organ Impairments / Disorders Enabled Based on Infusion Type
4/24/2026	2814: Indication for CIBMTR Data Reporting	Add	Clarified how to report the date of infusion when planned to be administered over multiple days in Q12: This question is answered for all infusion types except for autologous rescues and DLIs. Report the planned date of transplant. If the plan was to infuse the product over multiple days, report the planned first date of infusion. An approximate date is fine to report if the date is not yet on the hospital schedule. When or if the approximated or planned date of infusion changes, the form should be updated in FormsNet3SM, as this data field is used to populate the date of infusion on the recipient’s other data collection forms.
4/24/2026	Reporting Instructions Overview: Contact Dates – Subsequent Infusions and Contact Dates	Modify	Example 5 updated to a new example. The prior example 5 is now example 7: Example 5: The recipient had a subsequent allo transplant for poor graft function. – The recipient has their first allo transplant on 3/1/2023 and a subsequent allo transplant from the same donor for the indication of poor graft function / insufficient donor chimerism on 4/15/2023. – Report the Day 100 contact date as the appropriate date for the reporting period since a new Pre-TED (2400) / Disease Classification (2402) is not required for allo boosts.
4/24/2026	Reporting Instructions Overview: Contact Dates – Subsequent Infusions and Contact Dates	Modify	Example 6 updated to a new example. The prior example 6 is now example 8: Example 6: The recipient had a subsequent allo transplant for poor graft function and death occurred in the same reporting period. – The recipient had their first allo transplant on 3/1/2023 and a subsequent allo transplant form the same donor for poor graft function / insufficient donor chimerism recovery on 4/15/2023; however, the recipient passed away on 5/20/2023. – Report the Day 100 contact date as the death, 5/20/2023.
4/24/2026	2030 SCD Pre-Infusion	Modify	Time frame for reporting transcranial doppler velocity updated in Q70 – 72: Transcranial doppler and transcranial color doppler are types of ultrasonography that measure the velocity of blood flow through the brain’s blood vessels by measuring the echoes of ultrasound waves moving trans-cranially. Indicate if transcranial doppler velocity was assessed at the time of diagnosis for the reported CNS event at any time prior to the start of the preparative regimen. If Yes, report the date of the assessment and the transcranial doppler velocity value in cm / sec. If transcranial doppler velocity was not assessed or if no information is available to determine if transcranial doppler velocity was assessed at the time of diagnosis for the reported CNS event, report No or Unknown, respectively.
4/24/2026	2400: Pre-TED	Add	Updated the non-myeloablative fludarabine + TBI regimen in table 1: Fludarabine + TBI < 200 cGY (single)
4/24/2026	Appendix J: Reporting Comorbidities	Add	Example 1: PFT Report and Dinakara Calculator added.
4/24/2026	Appendix J: Reporting Comorbidities	Modify	Updated Dinakara Equation blue box: Dinakara Equation: Use the following equation to adjust an uncorrected DLCO where the hemoglobin (measured in g/dL) is the closest value to the PFT assessment date (measured in g/dL): corrected DLCO= uncorrected DLCO/(0.06965*hemoglobin) If a hemoglobin value is not available from the same date of the PFT, use the most recent hemoglobin closest to the PFT date.
4/24/2026	LYM Response Criteria	Add	Clarified the splenomegaly threshold for radiographic PR and added example 1: If splenomegaly is present, a > 50% decrease in spleen length beyond normal (13 cm) is also required to report a partial radiological remission – Example 1: Splenomegaly and PR – Baseline maximum spleen length: 18 cm – Normal cutoff: 13 cm – Excess: 5 cm – 50 % regression of excess: 50 % of 5 cm = 2.5 cm – PR threshold: 18 cm – 2.5 cm = 15.5 cm – In this example, if splenomegaly is still present at the time of assessment, the spleen must measure less than 15.5 cm to meet PR criteria.
4/24/2026	Reporting Instructions Overview: GVHD	Add	Updated Lower GI GVHD ad Stool Output Not Document blue box in Acute GVHD section: Lower GI GVHD and Stool Output Not Documented: If diarrhea is attributed to acute GVHD during the reporting period, but the volume of stool output is not documented and the provider does not document a stage, leave the lower GI stage data field blank, override the FormsNet3 error as “not documented,” and specify the volume of stool output was not documented. In this case, report Not applicable for the overall grade unless stage 4 acute skin GVHD, stage 4 acute liver GVHD, or an extreme decrease in performance status or stage 2 or 3 acute liver GVHD was also documented at the time point being reported (at diagnosis or maximum grade during the current reporting period.
4/24/2026	2402: Disease Classification	Modify	Instructions for when to report the ISS for the first infusion updated in Q524: This question is only enabled if this is the first CIBMTR reported infusion of the primary disease for infusion. If the serum β2-microglobulin and serum albumin at diagnosis were reported, which are needed to calculate the I.S.S. staging, leave this data field blank and override the error as ‘verified correct. and none of the components needed to calculate the I.S.S. staging were reported elsewhere on the Disease Classification (2402) form.
4/24/2026	2402: Disease Classification	Modify	Instructions for when to report the R-ISS for the first infusion updated in Q525: This question is only enabled if this is the first CIBMTR reported infusion of the primary disease for infusion. If the serum β2-microglobulin, serum albumin, LDH, and FISH at diagnosis were reported, which are needed to calculate the R-I.S.S. staging, leave this data field blank and override the error as ‘verified correct.’ and none of the components needed to calculate the R-I.S.S. staging is not reported elsewhere on the Disease Classification (2402) form.
4/24/2026	2402: Disease Classification	Modify	Instructions for when to report the Durie-Salmon for the first infusion updated in Q526: This question is only enabled if this is the first CIBMTR reported infusion of the primary disease for infusion. If the I.S.S. has already been reported or if all laboratory values required to calculate the I.S.S. and R I.S.S. (serum ß2 microglobulin, serum albumin, LDH, and FISH) have already been reported, leave this field blank and override the error as ‘verified correct.’ the I.S.S. stage is not reported and none of the components needed to calculate the Durie-Salmon staging is not reported elsewhere on the Disease Classification (2402) form. Indicate Durie-Salmon stage and sub classification at diagnosis. If the Durie-Salmon stage and / or sub classification is not documented in the medical record, use the table below to determine the appropriate stage.
4/24/2026	Appendix D: How to Distinguish Infusion Types	Add	Image 1. Determining Which Forms Come Due for Subsequent Infusions added
4/24/2026	Appendix J: Reporting Comorbidities	Add	Added a link to the Adjusted DLCO Requirement red warning box to calculate the adjusted DLCO: Adjusted DLCO Requirements: As of the Winter 2026 quarterly release (January 23, 2026), the Dinakara equation for calculating the adjusted DLCO is required to be used when assessing if the criteria for the pulmonary comorbidity is met. If the PFT does not use the Dinakara equation or it is unknown if used, calculate the adjusted DLCO using the equation provided below or the calculator created by Fred Hutch found here.
4/24/2026	2116: PCD Post-Infusion	Modify	Clarified which assessment date to report when the best response date has not been previously reported in Q4: Indicate if the best response was reported on a previous post-HCT plasma cell disorder form (Form 2116). If Yes, and the recipient has a preceding / concurrent diagnosis of amyloidosis (question 2) continue with question 6. If not, continue with question 142. If the best response achieved during the 100-day reporting period is the same as the pre-transplant disease status, select No, report the latest first disease assessment that confirmed the ongoing disease status post-HCT in question 5. For all subsequent reporting periods, report Yes, until a better disease response is achieved. If the recipient’s pre-transplant disease status was Continued complete response (CCR), select No, report the date of the first assessment that confirmed the ongoing CR in question 5 on the 100-day form. For all subsequent reporting periods, report Yes.
4/24/2026	2402: Disease Classification	Remove	Further clarified how to report germ cell and non-germ cell tumors of the ovaries and testes: CIBMTR captures the classification for solid tumors based on the World Health Organization (WHO) 2022 classification. Indicate the solid tumor disease classification at the time of diagnosis. Germ cell tumors that originate in the ovary or testes should be reported as ovarian or testicular, respectively. If the subtype is not listed, report as Other solid tumor and specify the reported malignancy. Report germ cell tumors originating in the ovaries or testes as Germ cell tumor, gonadal. Report ovarian non-germ cell tumors as Ovarian (epithelial) and testicular non-germ cell tumors as Testicular.
4/24/2026	2400: Pre-TED	Modify	Clarified how to report the recipient’s highest degree or level of school: Select the option that best describes the recipient’s highest degree obtained / highest level of school completed at the start of the preparative regimen (or infusion if no preparative regimen was given). When reporting the highest degree obtained, select the degree or credential that has been completed at the time of the preparative regimen. When reporting the highest level of school completed, report the most advanced grade the recipient finished at the time of the preparative regimen using the following guidelines: – Under school age or no schooling: Recipient has not completed the 1st grade (including recipients who never attended school or who started 1st grade but did not complete it). – Up to 8th grade: Recipient completed at least 1st grade and up to and including 8th grade, but did not complete any grade beyond 8th. – 9th to 12th grade, no diploma: Recipient completed at least one grade between 9th and 12th but has not obtained a high school diploma or equivalent.
4/24/2026	2402: Disease Classification	Add	Table 2. Examples of Molecular Markers Associated with ALL added above Q148
4/24/2026	2039: HLH Pre-HCT	Add	Diagnosis Date red warning box added above Q3: Diagnosis Date: What was the date of diagnosis is disabled as this information is collected on the Disease Classification (2402).
4/24/2026	2034: XLP Pre-HCT	Add	Diagnosis Date red warning box added above Q3: Diagnosis Date: What was the date of diagnosis is disabled as this information is collected on the Disease Classification (2402).
4/24/2026	2033: WAS Pre-HCT	Add	Diagnosis Date red warning box added above Q1: Diagnosis Date: What was the date of diagnosis is disabled as this information is collected on the Disease Classification (2402).
4/24/2026	2031: ID Pre-HCT	Add	Diagnosis Date red warning box added above Q1: Diagnosis Date: What was the date of diagnosis of Immune Deficiency (ID)? is disabled as this information is collected on the Disease Classification (2402).
4/24/2026	2030 SCD Pre-Infusion	Add	Diagnosis Date red warning box added above Q3: Diagnosis Date: Date of diagnosis is disabled as this information is collected on the Disease Classification (2402).
4/24/2026	2029: Fanconi Anemia / Constitutional Anemia Pre-HCT	Add	Diagnosis Date red warning box added above Q1: Diagnosis Date: What was the date of diagnosis of Fanconi Anemia is disabled as this information is collected on the Disease Classification (2402).
4/24/2026	Reporting Instructions Overview: Contact Dates – Subsequent Infusions and Contact Dates	Modify	Example 10 updated: Example 10: The recipient had a subsequent Donor Lymphocyte Infusion (DLI) or subsequent allogeneic boost. The recipient has their first transplant on 1/21/22 and receives a DLI or allogeneic boost on 2/27/2022. Lymphodepleting therapy or preparative regimen may or may not be given and does not affect the contact date. Report the Day 100 contact date as a date appropriate to the reporting period. A DLI (2199) form should be completed for each DLI or allogeneic boost received in the reporting period. The Post-TED (2450) or Post-Infusion follow up (2100) form should not be completed early to report a DLI or allogeneic boost.
4/24/2026	Reporting Instructions Overview: Contact Dates – Subsequent Infusions and Contact Dates	Modify	On Demand DCI Reporting blue box updated above example 10: On Demand DLI DCI Reporting: DLIs and allogeneic boosts can be reported prior to the Post-TED (2450) or Post-Infusion Follow Up (2100) Form due date by creating a Indication for CIBMTR Data Reporting (2814) Form on demand. When the Post-TED (2450) or Post-Infusion Follow Up (2100) form is completed at the due date, and no other infusions were given in the reporting period, report the DLI as a subsequent infusion, which will create a new Indication for CIBMTR Data Reporting (2814) Form. Submit a ticket via CIBMTR Center Support to request the form be made NRQ.
3/27/2026	3504: Organ Function / Late Effects	Add	Version 1 Organ Function / Late Effects (3504) section of the Forms Instructions Manual released. Version 1 corresponds to revision 1 of the Form 3504.
3/27/2026	2158: Thalassemia Post-Infusion	Add	Version 3 of the 2158: Thalassemia Post-Infusion section of the Forms Instructions Manual released. Version 3 corresponds to revision 3 of the Form 2158.
3/27/2026	2058: Thalassemia Pre-Infusion	Add	Version 3 of the 2058: Thalassemia Pre-Infusion section of the Forms Instructions Manual released. Version 3 corresponds to revision 3 of the Form 2058.
3/27/2026	2100:Post-Infusion Follow-Up Form	Modify	Version 10 of the 2100: Post-Infusion Follow-Up section of the Forms Instructions Manual released. Version 10 corresponds to revision 10 of the Form 2100
3/27/2026	2000: Recipient Baseline	Modify	Version 5 of the 2000: Recipient Baseline section of the Forms Instruction Manual released. Version 5 corresponds to revision 7 of the Form 2000.
3/27/2026	Reporting Instructions Overview: GVHD	Add	Example 10 and 11 added
2/20/2026	4100: Cellular Therapy Essential Data Follow-Up	Add	Version 10 of the Cellular Therapy Essential Data Pre- Infusion section of the Forms Instructions Manual released. Version 10 corresponds to revision 10 of the Form 4100.
2/20/2026	2146: Fungal Infection Post-Infusion Data	Modify	Version 3 of the 2146: Fungal Infection Post-Infusion Data section of the Forms Instructions Manual released. Version 3 corresponds to revision 5 of the Form 2146.
2/20/2026	2046: Fungal Infection Pre-Infusion Data	Modify	Version 3 of the 2046: Fungal Infection Pre-Infusion Data section of the Forms Instructions Manual released. Version 3 corresponds to revision 6 of the Form 2046.
1/23/2026	2100:Post-Infusion Follow-Up Form	Modify	Updated the Combined Follow Up blue box in Q384: Combined Follow Up and Functional Status: In scenarios where a cellular therapy is given after a HCT and this form is being completed based on the subsequent cellular therapy, these questions do not apply and are disabled and should be answered.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Organ Function blue box added to Q250 – 377: Combined Follow Up and Organ Function: In scenarios where an HCT was given after a cellular therapy and this form is now being completed based on the subsequent HCT date, these questions still apply and should be answered.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Current GVHD Status blue box added to Q205: Combined Follow Up and Current GVHD Status: In scenarios where an HCT was given after a cellular therapy and this form is now being completed based on the subsequent HCT date, these questions still apply and should be answered.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Chronic GVHD blue box added in Q135: Combined Follow Up and Chronic GVHD: In scenarios where an HCT was given after a cellular therapy and this form is now being completed based on the subsequent HCT date, chronic GVHD will always be reported on the Post-Infusion Follow-Up (2100) Form and is disabled on the Cellular Therapy Essential Data Follow- Up (4100) Form.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Acute GVHD blue box added in Q86: Combined Follow Up and Acute GVHD: In scenarios where an HCT was given after a cellular therapy and this form is now being completed based on the subsequent HCT date, acute GVHD will always be reported on the Post-Infusion Follow-Up (2100) Form and is disabled on the Cellular Therapy Essential Data Follow-Up (4100) Form.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Immune Reconstitution blue box added: Combined Follow Up and Immune Reconstitution: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Updated Combined Follow Up blue box in Q30: Combined Follow-Up: In scenarios where a cellular therapy is given after a HCT and this form is being completed based on the subsequent cellular therapy, these questions do not apply and are disabled if there is a corresponding Post-Cellular Therapy Follow-Up 4101) Form.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Growth Factor and Cytokine Therapy blue box added to Q21: Combined Follow Up and Growth Factor and Cytokine Therapy: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Survival Status blue box added to Q2: Combined Follow Up and Survival Status: When both HCT and cell therapy forms are being completed, the survival status on the Post-Infusion Follow-Up (2100) Form should match the corresponding the Post-CTED (4100) Form.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Subsequent Infusion blue box added to Q3: Combined Follow Up and Subsequent Infusion: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, subsequent infusions are reported on the Post-Infusion Follow-Up (2100) Form and the question is disabled on the Cellular Therapy Essential Data Follow- Up (4100) Form.
1/23/2026	2100:Post-Infusion Follow-Up Form	Add	Combined Follow Up and Contact Date blue box added to Q1: Combined Follow Up and Contact Date: When both HCT and cell therapy forms are being completed, the date of contact on the Post-Infusion Follow-Up (2100) Form should match the corresponding the Post-CTED (4100) Form.
1/23/2026	2450: Post-TED	Add	Combined Follow Up and FMT blue box added to Q92: Combined Follow Up and FMT: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.
1/23/2026	2450: Post-TED	Add	Combined Follow Up and Liver Toxicity Prophylaxis blue box added in Q34: Combined Follow-Up and Liver Toxicity Prophylaxis: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.
1/23/2026	2450: Post-TED	Add	Combined Follow Up and VOD / SOS blue box added in Q37: Combined Follow-Up and VOD / SOS: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.
1/23/2026	2450: Post-TED	Modify	Combined Follow Up blue box updated in Q9: Combined Follow Up GVHD: In scenarios where a CT was given after an HCT and this form is now being completed based on the subsequent CT date, GVHD will always be reported on the Post-TED (2450) Form and is disabled on the Cellular Therapy Essential Data Follow-Up (4100) Form. In scenarios where both HCT and cell therapy forms are being completed, GHVD questions are disabled on the Cellular Therapy Essential Data Follow-Up (4100) form and should be answered on the Post-TED (2450).
1/23/2026	2450: Post-TED	Add	Combined Follow Up and Secondary Graft Failure blue box added in Q6: Combined Follow Up and Secondary Graft Failure: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, Did secondary graft failure occur? still applies and should be answered.
1/23/2026	2450: Post-TED	Modify	Combined Follow Up blue box updated in Q3: Combined Follow Up and Subsequent Infusion: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, subsequent infusions are always reported on the Post-TED (2450) Form and the question is disabled on the Cellular Therapy Essential Data Follow-Up (4100) Form. When both HCT and cell therapy forms are being completed, the subsequent infusion question is disabled on the Cellular Therapy Essential Data Follow-Up (4100) form and should be answered on the Post-TED (2450).
1/23/2026	2450: Post-TED	Add	Combined Follow Up and Survival Status blue box added to Q2: Combined Follow Up and Survival Status: When both HCT and cell therapy forms are being completed, the survival status on the Post-TED (2450) Form should match the corresponding Post-CTED (4100) Form. If death occurred in the reporting period, Death must be reported as the survival status on both the HCT and cellular therapy forms. Two Recipient Death (2900) Forms will come due; however, only one form needs to be completed. Contact CIBMTR Center Support to remove the duplicate.
1/23/22026	3505: Transfusion	Add	Added to the intro when this form will come due: This form will come due for those recipients enrolled onto CIBMTR study CS22-24 (Zyntelgo®). This is a post marketing prospective, multicenter, observational, long-term safety and effectiveness registry study of recipients with beta-thalassemia treated with Betibeglogene Autotemcel (Zynteglo®) and CIBMTR study CS20-55 (Casgevy®): Long-term registry-based study of patients with transfusion-dependent β-thalassemia (TDT) or sickle cell disease (SCD) treated with exagamglogene autotemcel (CasgevyTM).
1/23/2026	2199: Donor Lymphocyte Infusion	Modify	Updated the Partial Response and Complete Response criteria for suboptimal donor chimerism in Table 1 (Q38): PR: Increase in CD33 and or CD3 chimerism but not 95% donor chimerism; CR: > 95% donor chimerism in CD33 and or CD3
1/23/2026	2400: Pre-TED	Add	Dosing Weight Disabled blue note box added to Q143: Dosing Weight Disabled: With the Winter 2026 release (January 23, 2026), the Dosing weight used for preparative regimen orders question is disabled..
1/23/2026	Appendix J: Reporting Comorbidities	Modify	Replaced To Correct and Uncorrected DLCO blue note box with Dinakara Equation blue note box: To correct an uncorrected DLCO: corrected DLCO= uncorrected DLCO/(0.06965*hemoglobin) where hemoglobin is measured in g/dL Dinakara Equation: Use the following equation to adjust and uncorrected DLCO where the hemoglobin is the closest value to the PFT assessment date (measured in g/dL): corrected DLCO= uncorrected DLCO/(0.06965*hemoglobin)
1/23/2026	Appendix J: Reporting Comorbidities	Modify	Clarified when the Dinakara equation shoud be used: For instances in which the pulmonary function testing report does not correct diffusing capacity of carbon monoxide for hemoglobin, use the Dinakara equation to correct. When determining if a pulmonary comorbidity is present, the Dinakara equation for calculating the adjusted DLCO must be used to assess if the criteria for the pulmonary comorbidity is met. If it is unclear if the PFT utilizes the Dinakara equation, seek clinician / lab clarification. If the PFT does not use the Dinakara equation when determining the adjusted DLCO, calculate the adjusted DLCO using the Dinakara and use the calculated value when determining if the pulmonary comorbidity criteria is met.
1/23/2026	Appendix J: Reporting Comorbidities	Add	Adjusted DLCO Requirements red warning box added: Adjusted DLCO Requirements: As of the Winter 2026 quarterly release (January 23, 2026), the Dinakara equation for calculating the adjusted DLCO is required to be used when assessing if the criteria for the pulmonary comorbidity is met. If the PFT does not use the Dinakara equation or it is unknown if used, calculate the adjusted DLCO using the equation provided below.
1/23/2026	Appendix J: Reporting Comorbidities	Add	What to Report table updated to clarify the Dinakara equation is required to be used when determining if a pulmonary (moderate or severe) comorbidity is present). Adjusted DLCO 66 – 80% / < 65%, using the Dinakara equation (See Adjusted DLCO Requirements red warning box below)
1/23/2026	Appendix J: Reporting Comorbidities	Modify	Reformatted the instructions provided outside of What to Report and What Not to Report tables for better instruction flow.
1/23/2026	2450: Post-TED	Add	Non-US Centers and Platelet Recovery red warning box added: Non-US Centers and Platelet Recovery: Prior to the Fall 2025 release (October 24, 2025), the platelet recovery questions were optional for non-US centers. However, as of October 24, 2025, this question is now required to be answered for all centers. If completing the Post-TED (2450) Form for a six-month or annual reporting period and the previously completed Post-TED (2450) Form did not require the platelet question to be answered, leave the Was an initial platelet count > 20 × 109/L achieved question blank and override the error as ‘verified correct.’
1/23/2026	2100:Post-Infusion Follow-Up Form	Modify	Updated example 3 in Q383: Example 3: A recipient was diagnosed with basal cell skin cancer on the neck in the one-year reporting period and two months later, within the same reporting period, there was a diagnosis of basal cell located on the nose. The lesion on the nose is not considered a metastasis from the neck, but a new discreet lesion. Report Yes, there was a new malignancy on the Post-HCT Follow-Up (2100) and a single Subsequent Neoplasms (3500) form will come due to report one of the basal cell malignancies. Create a second Subsequent Neoplasms (3500) form to report the other basal cell malignancy as these are discreet episodes. A recipient was diagnosed with basal cell skin cancer on the neck in the one-year reporting period and two months later, within the same reporting period, there was a diagnosis of basal cell located on the nose. The lesion on the nose is not considered a metastasis from the neck, but a new discrete lesion. In the two-year reporting period, the recipient was diagnosed with an additional basal cell skin cancer on the arm. For the one-year reporting period, report Yes, there was a new malignancy on the Post-Infusion Follow-Up (2100) Form, a single Subsequent Neoplasms (3500) Form will come due, and report 2 for the total number of non-melanoma lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500). For the two-year reporting period, report Yes, there was a new malignancy on the Post-Infusion Follow-Up (2100) Form, a single Subsequent Neoplasms (3500) Form will come due, and report 1 for the total number of non-melanoma lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500).
1/23/2026	2100:Post-Infusion Follow-Up Form	Modify	Replaced Recurrent Skin Cancers blue note box with Recurrent Non-Melanoma Skin Cancers blue note box in Q383: Recurrent Skin Cancers: For most malignancies, do not report recurrence, progression, or transformation of the recipient’s primary disease (disease for which the transplant was performed) or relapse of a prior malignancy in the “New Malignancy” section. However, in the case of a basal cell or squamous cell skin cancer, report each discreet episode as a new malignancy. See Example 3 below for additional information. Recurrent Non-Melanoma Skin Cancers: If there is a recurrence of non-melanoma skin cancers in the reporting period, select Yes for Did a new malignancy, myeloproliferative, or lymphoproliferative disease / disorder occur that is different from the disease / disorder for which the HCT or cellular therapy was performed and a single Subsequent Neoplasms (3500) will come due, allowing the total number of non-melanoma skin cancer lesions diagnosed during the reporting period to be reported. If additional non-melanoma skin cancer lesions are diagnosed in the reporting period, update the reported total number of non-melanoma skin cancer lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500). Do not create separate Subsequent Neoplasms (3500) forms for each discrete lesion diagnosed in the reporting period. If a non-melanoma skin cancer is diagnosed again in a future reporting period, repeat the process for that reporting period.
1/23/2026	2450: Post-TED	Modify	Updated example 3 in Q39: Example 3: A recipient was diagnosed with basal cell skin cancer on the neck in the one-year reporting period and two months later, within the same reporting period, there was a diagnosis of basal cell located on the nose. The lesion on the nose is not considered a metastasis from the neck, but a new discreet lesion. Report Yes, there was a new malignancy on the Post-TED (2450) Form, and a single Subsequent Neoplasms (3500) Form will come due to report one of the basal cell malignancies. Create a second Subsequent Neoplasms (3500) form to report the other basal cell malignancy as these are discreet episodes. A recipient was diagnosed with basal cell skin cancer on the neck in the one-year reporting period and two months later, within the same reporting period, there was a diagnosis of basal cell located on the nose. The lesion on the nose is not considered a metastasis from the neck, but a new discrete lesion. In the two-year reporting period, the recipient was diagnosed with an additional basal cell skin cancer on the arm. For the one-year reporting period, report Yes, there was a new malignancy on the Post-TED (2450) Form, a single Subsequent Neoplasms (3500) Form will come due, and report 2 for the total number of non-melanoma lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500). For the two-year reporting period, report Yes, there was a new malignancy on the Post-TED (2450) Form, a single Subsequent Neoplasms (3500) Form will come due, and report 1 for the total number of non-melanoma lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500).
1/23/2026	2450: Post-TED	Modify	Replaced Recurrent Skin Cancers blue note box with Recurrent Non-Melanoma Skin Cancers blue note box in Q39: Recurrent Skin Cancers: For most malignancies, do not report recurrence, progression or transformation of the recipient’s primary disease (disease for which the infusion was performed) or relapse of a prior malignancy in the “New Malignancy” section. However, for recurrent skin cancers, each discrete lesion should be reported. For example, in the six-month reporting period, a recipient was diagnosed with basal cell skin cancer on the neck four months post-infusion and in the one-year reporting, the recipient was diagnosed with another basal cell located on the nose. The lesion on the nose is not considered a metastasis from the neck, but a new discrete lesion. These discrete episodes should be reported as a ‘new malignancy’ on the Post-TED (2450) Forms. Recurrent Non-Melanoma Skin Cancers: If there is a recurrence of non-melanoma skin cancers in the reporting period, select Yes for Did a new malignancy, myeloproliferative, or lymphoproliferative disease / disorder occur that is different from the disease / disorder for which the HCT or cellular therapy was performed and a single Subsequent Neoplasms (3500) will come due, allowing the total number of non-melanoma skin cancer lesions diagnosed during the reporting period to be reported. If additional non-melanoma skin cancer lesions are diagnosed in the reporting period, update the reported total number of non-melanoma skin cancer lesions diagnosed in the reporting period on the Subsequent Neoplasms (3500). Do not create separate Subsequent Neoplasms (3500) forms for each discrete lesion diagnosed in the reporting period. If a non-melanoma skin cancer is diagnosed again in a future reporting period, repeat the process for that reporting period.
1/23/2026	2012: CML Pre-Infusion Data	Modify	Corrected time point for reporting molecular results in Q148 – 149: If testing for molecular markers was performed at diagnosis the time of best response, report “yes” and indicate the sample collection date in question 149. If the exact date is not known, use the process described for reporting partial or unknown dates in General Instructions, General Guidelines for Completing Forms. If no molecular marker testing was performed or it is unknown if testing was done, report “no” or “unknown” respectively and go to question 179.
1/23/2026	2450: Post-TED	Modify	Updated Chimerism Studies blue info box above Q40: This section relates to chimerism studies from allogeneic HCTs using cord blood units, or for allogeneic HCT recipients whose primary disease is beta thalassemia or sickle cell disease only a non-malignant. If this was an autologous HCT, an allogeneic HCT using a bone marrow or PBSC product, and / or allogeneic HCT recipient whose primary disease for transplant was not beta thalassemia or sickle cell disease a non-malignant disease, continue to the disease assessment section.
1/23/2026	CML Response Criteria	Modify	Chronic phase and CR criteria updated: Chronic Phase: Characterized by relatively few blasts (<10%) present in the blood and or bone marrow. Symptoms are often not present. The chronic phase may last several months to years, depending on the recipient and the treatment they receive. ; CR: Hematologic complete remission is defined as a treatment response where all of the following criteria are met: White blood count is < 10 × 109/L, without immature granulocytes and with < 5% basophils Platelet count < 450 × 109/L Non-palpable spleen
1/23/2026	2402: Disease Classification	Add	Clarified how to report germ cell and non-germ cell tumors of the ovaries and testes in Q559 – 560: CIBMTR captures the classification for solid tumors based on the World Health Organization (WHO) 2022 classification. Indicate the solid tumor disease classification at the time of diagnosis. Germ cell tumors that originate in the ovary or testes should be reported as ovarian or testicular, respectively. If the subtype is not listed, report as Other solid tumor and specify the reported malignancy. Report germ cell tumors originating in the ovaries or testes as Germ cell tumor, gonadal. Report ovarian non-germ cell tumors as Ovarian (epithelial) and testicular non-germ cell tumors as Testicular. If a certain disease becomes a common indication for infusion, the CIBMTR will add the disease as a separate category.
1/23/2026	2450: Post-TED	Add	Clarified how to report the initial therapy start date in Q90 when treatment was started prior to the addition of this question: Indicate if the initial therapy given for reasons other than decrease / loss of chimerism, consolidation therapy, MRD, relapse, persistent, or progressive disease was reported in a previous reporting period. The intent of this question is to capture the start date of the first maintenance therapy administered. If the initial start date was not reported in a prior reporting period, select No and report the initial therapy start date. If maintenance therapy was started, stopped, and restarted, report the date when the therapy first began. If a maintenance therapy was started and then switched to a different maintenance therapy, report the start date of the first maintenance therapy. If initial therapy was started in a previous reporting period and the prior Post-TED (2450) Form did not collect if the initial therapy date was previously reported, select Yes. The therapy start date is not captured for recipients who started their initial therapy prior to the addition of this question. If exact date is not known, refer to General Instructions, General Guidelines for Completing Forms for information about reporting partial or unknown dates.
1/23/2026	2451: Chimerism Essential Data	Add	Reporting the Same Cell Type Results Assessed by Different Samples and Reporting Multiple Other Cell Types blue boxes added above Q2 – 3.
1/23/2026	2400: Pre-TED	Add	Clarified Q12 intent: The intent of this question is to determine care access, regardless of the language spoken. Indicate if the recipient (or their parent, guardian, or legally authorized representative) requires interpreter services for any aspect of care, including verbal communication, reading, or other forms of assistance. Interpreters may include professional interpreters, family members, friends, or other individual who help facilitate communication.
1/23/2026	2450: Post-TED	Modify	Typo in Q32 – 33 instructions for reporting GVHD steroid treatment correct: These questions are intended to capture if the recipient was still receiving systemic steroids (steroid dose < 10 mg / day for adults, < < 0.1 mg / kg / day for children, excluding steroids for adrenal insufficiency) and non-steroid immunosuppressive agents for GVHD on the contact date. Indicate if the recipient was still taking systemic steroids (steroid dose < 10 mg / day for adults, < < 0.1 mg / kg / day for children, excluding steroids for adrenal insufficiency) and non-steroid immunosuppressive agents on the contact date. Review the GVHD Reporting Instruction Overview for reporting instructions to these questions.
1/23/2026	JMML Response Criteria	Add	JMML Disease Status Response Options red warning box and Table 1. JMML Disease Status Response Options table added

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.